Fludrocortisone Dose Response Relationship in Septic Shock - FluDReSS
Status:
Recruiting
Trial end date:
2022-12-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the most suitable dose of Fludrocortisone in
reversal of sepsis and shock associated with sepsis in patients who are admitted to the ICU.
The investigators will be looking to see whether patients receiving Fludrocortisone at
different doses recover quicker and spend less time in hospital and in ICU, and to understand
the reasons why this happens at certain doses.
Sepsis is caused by toxic substances (toxins) from bacteria and other organism entering the
bloodstream from a site of infection. In some people, the infection can progress to sepsis
and septic shock where the functions of organs in the body are affected. Patients suffering
from sepsis and septic shock are commonly managed in the intensive care unit (ICU) where they
are prescribed antibiotics as standard therapy, as well as other therapies to support the
functions of the body.
Fludrocortisone is a steroid that has previously shown to be beneficial to help in shock in
patients in ICU, but more information is required about the exact dose that is required to
achieve this. This has been shown by previous research.
However, the exact role of Fludrocortisone and the best dose has not been studied adequately
to date as well as the ways in how it works within the body. The study aims to look tat the
dose and the way it works.